Skip to main content
. 2022 Apr 19;126(11):1548–1554. doi: 10.1038/s41416-022-01737-2

Fig. 1. Design of the TASCO1 trial.

Fig. 1

BID twice daily, d days, ECOG Eastern Cooperative Oncology Group, IV intravenous, mCRC metastatic colorectal cancer, p.o. orally, PS performance status, qxd every x days, R randomisation.